Posted by Michael Wonder on 16 Jul 2020
Farxiga granted fast track designation in the US for heart failure following acute myocardial infarction leveraging an innovative registry-based trial design
16 July 2020 - Phase III DAPA-MI trial will evaluate Farxiga as a treatment to reduce mortality and the risk of heart failure following a heart attack.
AstraZeneca has been granted fast track designation in the US for the development of Farxiga (dapagliflozin) to reduce the risk of hospitalisation for heart failure or cardiovascular death in adults following an acute myocardial infarction or heart attack.
The designation is based on the Phase III DAPA-MI trial that will explore the efficacy and safety of Farxiga in this patient population.
Read AstraZeneca press release
